文献速递妇科

妇科癌症中免疫治疗与放射联合试验:潜在的协同作用?

Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
PubMed 文献 · Gynecol Oncol · 2019-04-14

本文综述免疫治疗药物在妇科癌症中的应用现状,阐述放疗通过释放肿瘤新抗原激活细胞毒性T细胞介导的适应性免疫反应的机制,并讨论免疫检查点阻断联合放疗在转移性和根治性治疗中的已报告和正在进行的临床试验策略。

要点

  • 放疗可释放肿瘤新抗原并激活细胞毒性T细胞介导的适应性免疫反应。
  • 远隔效应在临床实践中罕见,联合免疫检查点阻断正被研究以克服免疫耐受。
  • 妇科癌症是免疫检查点阻断的有吸引力的靶点,联合放疗策略正在转移性和根治性场景中评估。

核心结论

  • 免疫治疗是实体瘤治疗的重要新支柱,免疫治疗药物与化疗、靶向治疗、手术和放疗的整合尚未明确。
  • 放疗通过免疫致敏可能增强照射部位的局部肿瘤控制,并诱导控制远处转移的全身反应即远隔效应。
  • 妇科癌症是免疫检查点阻断的有吸引力的靶点,免疫治疗药物可与根治性放化疗联合以增强放射敏感性及局部控制,并与立体定向放疗联合用于转移性疾病。

研究设计与样本

  • 综述,检索范围包括已报告和正在进行的免疫治疗与放疗联合临床试验的临床观察和临床前研究。

主要发现

  • 放疗释放肿瘤新抗原并激活由细胞毒性T细胞介导的适应性免疫反应,T细胞归巢至照射和非照射肿瘤转移灶诱导免疫原性肿瘤细胞死亡。
  • 远隔效应在临床实践中罕见,联合免疫检查点阻断与放疗的策略正在研究中以克服免疫耐受或抑制并提高免疫治疗药物的全身缓解率。
  • 对于转移性疾病患者,免疫检查点阻断联合立体定向放疗正被评估作为免疫激活和肿瘤减积的策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy (IO) is an important new pillar in the treatment of solid tumors, and the integration of IO agents with chemotherapy, targeted therapy, surgery and radiation has yet to be defined. As preclinical and clinical studies have described synergistic activity with the combination of radiation and immunotherapy, many clinical trials are underway to explore both the safety and efficacy of this approach both in the metastatic and definitive setting. Through immune priming, radiation may enhance local tumor control at the irradiated site, as well as induce a systemic response to control distant metastasis, known as the abscopal effect. On a mechanistic level, radiation therapy releases tumor neoantigens and activates an adaptive immune response that is mediated by cytotoxic T-cells, which then hone to sites of irradiated tumor as well as non-irradiated tumor metastases to induce immunogenic tumor cell death. Although the abscopal effect is rare in clinical practice, strategies that combine immune checkpoint blockade with radiation are being studied to overcome immune tolerance or suppression and increase systemic response rates to IO agents. Gynecologic cancers are attractive targets for immune checkpoint blockade, and IO agents may be used in combination with definitive chemoradiotherapy to enhance radiosensitivity and thus local control for unresected disease as well as control distant micrometastatic spread. For patients with metastatic disease, immune checkpoint blockade in combination with stereotactic radiotherapy is being evaluated as a strategy for immune activation and tumor cytoreduction. In this review, we highlight the current use of IO agents in gynecologic cancer, describe the immunogenic potential of radiation through clinical observation and preclinical study, and discuss strategies for combining IO and radiation in reported and ongoing clinical trials.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lee L, Matulonis U. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy? Gynecol Oncol. 2019. PMID: 30995960. doi:10.1016/j.ygyno.2019.03.255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。